hit counter

Allopregnanolone Agonists for Depression: Brexanolone & Zuranolone in Focus (2023)

Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …

Read more

Fecal Microbiota Transplantation (FMT) for Depression Treatment: 2 Case Reports (Pilot Study)

Fecal microbiota transplantation (FMT) aims to modify the gut microbiome and holds promise as a new treatment approach for major depressive disorder (MDD). Early case studies report improvements in depressive symptoms following fecal microbiota transplantation (FMT), but larger controlled trials are needed to substantiate its efficacy. Key Facts: Two patients with long-standing major depression received …

Read more

At-Home TDCS (Transcranial Direct Current Stimulation) for Depression: A Convenient Treatment

A new study provides promising evidence that delivering transcranial direct current stimulation (tDCS) remotely in people’s homes could be an effective treatment approach for major depressive disorder. The key facts are: tDCS is a form of non-invasive brain stimulation that uses electrical currents to modulate activity in targeted brain regions. When applied to the left …

Read more

Adjunct Celecoxib for Depression & Mania: Treatment with a COX-2 Inhibitor

Celecoxib, a selective COX-2 inhibitor, shows promise as an effective and safe adjunct treatment for major depression and mania, according to a new comprehensive systematic review. The analysis also found celecoxib improved symptoms when used as a standalone antidepressant in patients with somatic disorders. However, evidence for efficacy in bipolar depression remains unclear. Key Facts: …

Read more

Case Report: Depression Treated with Deep Brain Focused Ultrasound (2023)

Deep brain stimulation using focused ultrasound leads to rapid remission of severe depression in breakthrough patient case study. Key Facts: Focused ultrasound targeted and suppressed hyperactive areas linked to depression. Stimulation lasted just 64 minutes yet caused depression remission for over 6 weeks. Approach is noninvasive and precisely targeted with no side effects observed. Technology …

Read more

Triple Reuptake Inhibitors For Depression: SNDRI Drugs Outlook

There is a newer class of antidepressant drugs called Triple Reuptake Inhibitors¬†(TRI’s or SNDRI drugs) being developed that target all major neurotransmitters involved in depression: serotonin, norepinephrine, and dopamine. The thought process behind the creation of this new class of triple reuptake inhibitors is that they will target all three major neurotransmitters that are thought …

Read more